Skip to main content Skip to search Skip to main navigation

EU: Procedures on Inspections and Exchange of Information in new Version 18

The European Commission has revised and restructured the Compilation of Community Procedures on Inspections and Exchange of Information. In addition to new content and editorial adjustments, the 295-page document has been divided into a Part I including procedural topics and a Part II containing interpretation documents and templates. The documents were last updated in 2014.

The compilation primarily serves a harmonised approach and to facilitate cooperation for inspections within the European Member States. It applies to both GMP and GDP inspections. The procedures outlined in the compilation in turn form the basis for national procedures that are part of the quality management systems of the national GMP inspectorates.

In Part I, these procedural topics have been revised in form of independent short documents:

  • Management and classification of reports of suspected quality defects in medicinal products and risk-based decision-making (new: provides more comprehensive guidance following quality risk management principles)
  • Procedure for managing rapid alerts arising from quality defects risk assessment
    (new: provides more comprehensive guidance following quality risk management principles)
  • Outline of a Procedure for Co-ordinating the Verification of the GMP Status of Manufacturers in Third Countries
  • The Issue and Update of GMP Certificates
  • A model for risk based planning for inspections of pharmaceutical manufacturers
  • Procedure for dealing with serious GMP non-compliance requiring co-ordinated measures to protect public or animal health (Procedure has been revised as a result of experience with the superseded procedure; Appendix 6: Supervisory Risk Assessment has been updated)
  • Procedure for dealing with serious GMP non-compliance information originating from third country authorities or international organisations

New in Part I:

  • Procedure for compliance management

In Part II revised interpretational documents and templates are:

  • Interpretation of the Union format for Manufacturer/Importer Authorisation
  • Interpretation of the Union format for GMP certificate
  • Interpretation of the Union format for a wholesale distribution authorisation (medicinal products for human use)
  • Union format for a GMP certificate
  • Statement of non-compliance with GMP

New in Part II:

  • Interpretation of the Union format for a wholesale distribution authorization (medicinal products for human use)

Source:
EU: CoCP on Inspections and Exchange of Informations

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EU: First Four EUDAMED Modules Mandatory from 28 May 2026

EU: First Four EUDAMED Modules Mandatory from 28 May 2026

With Commission Decision (EU) 2025/2371, the European Commission has formally declared that the first four EUDAMED modules meet the required functional specifications. Publication in the OJEU on 27 November 2025 activates the six-month transition period foreseen in Regulation (EU) 2024/1860.

Read more
Swissmedic: Digital Package Leaflet Instead of Paper

Swissmedic: Digital Package Leaflet Instead of Paper

From 1 December 2025, medicines intended solely for use by healthcare professionals no longer require a printed package leaflet. Instead, a QR code on the outer packaging must provide direct access to the professional information.

Read more
EMA: 6 New Nitrosamines for Appendix 1

EMA: 6 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.

Read more
How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
Previous
Next